Nature Biotechnology
19, 207 - 209 (2001)
doi:10.1038/85627
The end of the beginning for genomic medicineDavid Bailey, Edward Zanders
& Philip Dean
David Bailey is chief executive officer, Edward Zanders is vice president discovery genomics, Philip Dean is chief scientific officer at De Novo Pharmaceuticals, 59 St Andrews Street, Cambridge CB2 3DD, UK
(david.bailey@denovopharma.com). The human genome sequence yields several surprises for researchers seeking to exploit genomic data in drug discovery
|
